Abstract
Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) mediates a plethora of physiological and pathological activities via interactions with a series of high affinity G protein-coupled receptors (GPCR). Both LPA receptor family members and autotaxin (ATX/LysoPLD), the primary LPA-producing enzyme, are aberrantly expressed in many human breast cancers and several other cancer lineages. Using transgenic mice expressing either an LPA receptor or ATX, we recently demonstrated that the ATX-LPA receptor axis plays a causal role in breast tumorigenesis and cancer-related inflammation, further validating the ATX-LPA receptor axis as a rich therapeutic target in cancer.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Animals
-
Breast Neoplasms / complications
-
Breast Neoplasms / metabolism*
-
Female
-
Inflammation / etiology
-
Inflammation / metabolism*
-
Lysophospholipids / chemistry*
-
Lysophospholipids / metabolism
-
Mice
-
Mice, Transgenic
-
Models, Biological
-
Multienzyme Complexes / metabolism*
-
Phosphodiesterase I / metabolism*
-
Phosphoric Diester Hydrolases
-
Pyrophosphatases / metabolism*
-
Receptors, Lysophosphatidic Acid / metabolism*
-
Signal Transduction / physiology*
Substances
-
Lysophospholipids
-
Multienzyme Complexes
-
Receptors, Lysophosphatidic Acid
-
Phosphoric Diester Hydrolases
-
Phosphodiesterase I
-
alkylglycerophosphoethanolamine phosphodiesterase
-
Pyrophosphatases
-
lysophosphatidic acid